Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment

  • Franklin K. Johnson,
  • Shirley Wu,
  • Ginny Schmith,
  • Hadis Williams,
  • Jasmine Rutecki,
  • Atef Halabi,
  • Thorsten Feldkamp,
  • Anthony Sileno

In the Materials and methods section, the headings Pharmacokinetic sample collection, Analytical method, Noncompartmental analysis and Population pharmacokinetics analysis sections should have been the subheadings of the Study Treatment.

Tables 2 and 3 are formatted incorrectly. Please see the correct Tables 2 and 3 here.

thumbnail
Download:
Table 2. Summary of PK parameters of migalastat in plasma.

https://doi.org/10.1371/journal.pone.0322315.t002

thumbnail
Download:
Table 3. Summary of PK parameters of migalastat in dialysate and extraction from plasma by dialysis.

https://doi.org/10.1371/journal.pone.0322315.t003

S1 Checklist is uploaded incorrectly. Please view the correct S1 Checklist below.

Supporting information

S1 Checklist. TREND statement checklist.

https://doi.org/10.1371/journal.pone.0322315.s001

(PDF)

Reference

  1. 1. Johnson FK, Wu S, Schmith G, Williams H, Rutecki J, Halabi A, et al. Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment. PLoS One. 2024;19(12): e0314030. pmid:39636942

Citation: Johnson FK, Wu S, Schmith G, Williams H, Rutecki J, Halabi A, et al. (2025) Correction: Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment. PLoS ONE 20(4): e0322315. https://doi.org/10.1371/journal.pone.0322315

Published: April 8, 2025

Copyright: © 2025 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.